Table I.

HCC patient characteristics

Patient CodeAge/SexNumber of Tumor Lesions, SizeHistologyaSerologyHLA-A, -Bb
LAU 66970/maleSix lesions, diameters 18, 5.5, 2, 1.8, 1.6, and 0.8 cm; infiltration of neighbouring organsLow differentiation; moderate lymphocytic infiltrationHBs negative, anti-HBc negative, HCV negative, anti-HCV negativeA*0201, A24(9), B62(15), Bx
LAU 67468/maleThree lesions, largest lesion 3 × 2 × 2 cmModerate differentiation; slight lymphocytic inifiltration; liver cirrhosis.HBs negative, anti-HBc negative, anti-HCV positiveA*0201c, A3, B35, B51(5)
LAU 69875/maleTwo lesions, diameters 5 and 3.5 cmModerate differentiation; slight lymphocytic infiltrationHBs negative, anti-HBc negative, HCV negative, anti-HCV negativeA1, A*0201, B7, B37
LAU 74881/femaleOne lesion, diameter 13 × 6 × 5 cmLow differentiation; no lymphocytic infiltrationHBs negative, anti-HBc negative, anti-HCV negativeA*0201, A28, B18, B27
LAU 76670/maleMultiple lesions, diameters between 1 and 2 cmModerate differentiation; no lymphocytic infiltration; liver cirrhosisHBs negative, anti-HBc negative, anti-HCV positiveA*0201, A*31d
LAU 81268/femaleOne lesion, diameter 2 × 2 × 2 cmWell differentiated; strong lymphocytic infiltrationHBs negative, anti-HBc negative, anti-HCV negativeA*0201, A3, B13, B62(15)
  • a Tumor differentiation and cirrhosis was analyzed with H&E sections. Intratumoral T cell infiltration was analyzed with sections stained with CD3-specific Ab.

  • b HLA typing for HLA-A,-B was done by serology, and for A2 subtypes with HLA allele-sequence-specific primers.

  • c The rare alleles A*0259/60/64 cannot be excluded.

  • d The rare heterozygous combinations A*0258/59/60/64 and A*3109 cannot be excluded.